The timing of the exposure during pregnancy made a big difference in the level of risk associated with developing an allergic condition.

Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) of HRS9531.

SELLAS AML therapy achieved an overall response rate of 33%, exceeding the 20% threshold, with some patient groups achieving 50% ...

SPRIM PRO and ObvioHealth have announced an expansion of their partnership to provide a fully integrated trial solution.

Neurocrine Biosciences has presented new one-year data from its Phase III CAHtalyst Adult study of Crenessity for classic CAH.

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.

ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.

MSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.

Amylyx has presented new exploratory analyses from the Phase II PREVENT and Phase IIb trials of avexitide for PBH treatment.

Verastem has reported primary analysis data from the Phase II RAMP 201 trial, where the avutometinib combination showed an ORR of 31% ...

Crinetics Pharmaceuticals has revealed new data from its clinical development programme for Palsonify, an oral treatment for acromegaly.

Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have showed NeoVaxMI's improved immune response in melanoma patients.